Just as we suspected, BTG (BTG) is slowly getting its Varithena product off the ground in North America. The pharma group has admitted sales of Varithena across the US will be slower than first expected, due to reimbursement issues born out of 'ObamaCare', but things are looking brighter across the border.
IC TIP:
Buy
at
650p
BTG announced that Health Canada - the Canadian government's department for national health - has approved the varicose veins treatment. A commercial launch has been scheduled for the first half of 2016, and is expected to be available to the patient population of 3.7m people.
